Quantification of global FDG uptake as a novel imaging modality to assess Sarcoidosis in the diseased organs and the entire body

Conclusions: Currently, FDG-PET is not used as a first-line imaging modality in sarcoidosis, as it is considered to be of value for advanced and relapsing stages of the disease. However, having a score that allows assessment of global disease activity in the body will provide potential for expanding the clinical utility of FDG-PET to evaluate disease behavior, treatment response and disease relapse at any stage of this common inflammatory disorder.

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Al-zaghal, A., Jahangiri, P., Pournazari, K., Khosravi, M., Werner, T., Alavi, A. Tags: Educational Exhibits Source Type: research